Sancilio & Company, Inc. (SCI) is an integrated specialty pharmaceutical company. We are uniquely focused on diseases that impact fatty acid balance within the body and we have developed Advanced Lipid Technologies® (ALT®) to increase bioavailability of lipids and lipophilic materials while minimizing the effects of food on absorption and the liver.

Our most advanced applications of ALT® include:

  • Sickle Cell Disease* (SC411) – Our pediatric soft gelatin capsule formulation to treat vaso-occlusive crisis in Sickle Cell Disease
  • Severe Hypertriglyceridemia (SC401) – An ALT® super bioavailable formulation has been shown to reduce triglycerides by over 40% with a lower dose within 14 days. The formulation can be taken with or without food.
  • Pediatric Malabsorption* in Short Bowel Syndrome (SC403) – Our formulation added to enteral feeding to reduce the use of parenteral nutrition

* Orphan Drug Status granted by the U.S. FDA in 2015


Primary Contact

Marc Wolff
Executive Vice President & Chief Financial Officer
[email protected]


Google+   Likedin